Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Lunresertib by Repare Therapeutics for Metastatic Colorectal Cancer: Likelihood of Approval
Lunresertib is under clinical development by Repare Therapeutics and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...
Lunresertib by Repare Therapeutics for Ovarian Cancer: Likelihood of Approval
Lunresertib is under clinical development by Repare Therapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Repare Therapeutics's Lunresertib?
Lunresertib is a small molecule commercialized by Repare Therapeutics, with a leading Phase II program in Non-Small Cell Lung Cancer....
Risk adjusted net present value: What is the current valuation of Repare Therapeutics's Lunresertib?
Lunresertib is a small molecule commercialized by Repare Therapeutics, with a leading Phase II program in Gastroesophageal (GE) Junction Carcinomas....